Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 83
Filter
1.
Bone Marrow Transplant ; 43(3): 207-15, 2009 Feb.
Article in English | MEDLINE | ID: mdl-18806837

ABSTRACT

Unrelated umbilical cord blood (UCB) is an alternative stem cell source for paediatric patients lacking a matched related or unrelated marrow donor. We report the results of all paediatric unrelated UCB transplants performed in Australia and New Zealand over a 10-year period. A total of 135 patients were transplanted, 100 for malignant disease (74%) and 35 for non-malignant disorders. The majority (88%) of patients received an HLA-mismatched graft. The median infused total nucleated cell dose was 4.7 x 10(7)/kg and CD34+ count 1.9 x 10(5)/kg. Neutrophil engraftment occurred in 83% of patients by day 42 (median 23 days) and platelet engraftment in 55% by day 60 (median 56 days). Grades II-IV and III-IV acute GVHD occurred in 41 and 18% of patients, respectively. TRM and overall survival 1-year post transplant were 32 and 61%, respectively. A higher probability of neutrophil recovery (P=0.004) and faster time to recovery (median 18 days vs 26 days, P=0.008) were observed in recipients of a cord unit with a CD34 cell dose >or=1.7 x 10(5)/kg. Our results support selection of cord units with CD34 cell doses >or=1.7 x 10(5)/kg to promote faster engraftment, improve survival and lower TRM.


Subject(s)
Cord Blood Stem Cell Transplantation , Fetal Blood/transplantation , Hematologic Diseases/therapy , Antigens, CD34/blood , Antigens, CD34/immunology , Child , Child, Preschool , Fetal Blood/immunology , Graft vs Host Disease/immunology , Hematologic Diseases/prevention & control , Hematopoiesis , Humans , Neutrophils/immunology , Neutrophils/transplantation , Regression Analysis , Retrospective Studies , Survival Rate , Treatment Outcome
2.
Bone Marrow Transplant ; 40(8): 741-6, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17724446

ABSTRACT

We retrospectively analysed the outcomes of children transplanted for high-risk neuroblastoma (NB) at a single institution predominantly transplanted with total body irradiation and chemotherapy. The aims of this study were to determine the prognostic impact of clinical and biological features and to document long-term health outcomes. Forty patients were transplanted with a single unpurged autograft. Fourteen patients died from disease progression and two from late complications of treatment. Twenty-three patients are alive at a median of 4.6 years from diagnosis. Kaplan-Meier estimates of overall survival at 2, 5 and 10 years are 76+/-7.0, 60.2+/-8.4 and 54.7+/-9.3% following transplant. Response to induction therapy was significantly associated with survival (P<0.01). Long-term complications included growth (100%) and pubertal failure (83%), hearing impairment (73%), orthopaedic complications (63%), renal impairment (47%) and thyroid abnormalities (36%). Intrinsic and acquired resistance to chemotherapy remains the major obstacle to improving outcomes in high-risk NB. Although patients with chemo-sensitive disease are less likely to experience a relapse, substantial therapy-related toxicities result in poor long-term health outcomes for survivors.


Subject(s)
Neuroblastoma/therapy , Stem Cell Transplantation , Child , Child, Preschool , Female , Humans , Infant , Infant, Newborn , Male , Retrospective Studies , Stem Cell Transplantation/adverse effects , Survival Analysis , Transplantation Conditioning , Transplantation, Autologous , Treatment Outcome
3.
Bone Marrow Transplant ; 40(8): 729-34, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17700599

ABSTRACT

Over the past decade umbilical cord blood (UCB) has been increasingly used as a source of haematopoietic stem cells (HSCs) for patients who require a HSC transplant but do not have an HLA-matched donor. It was anticipated that using UCB as an alternative source of HSCs would increase the chance of finding a donor, particularly for the otherwise underrepresented ethnic minority groups. To evaluate the effectiveness of the Australian public UCB banks to increase the ethnic diversity of available HSC donations, this paper analyses the ethnic diversity of the Sydney Cord Blood Bank (SCBB), comparing this diversity to that of the Australian Bone Marrow Donor Registry (ABMDR). It also examines the ethnic diversity of those patients who, after requesting a haematopoietic stem cell transplantation in the 2-year period between 2003 and 2005, managed to find a suitably matched bone marrow or UCB donor. We show that the ethnic mix of donors to the SCBB has remained generally broad in source, is comparative to the Australian population, and is more diverse than the ABMDR. This, however, may still not be sufficient to substantially increase the likelihood of finding a donor for some ethnic minority groups.


Subject(s)
Blood Banks , Cord Blood Stem Cell Transplantation/ethnology , Fetal Blood , Public Health , Tissue Donors/statistics & numerical data , Australia , Cord Blood Stem Cell Transplantation/ethics , Humans , Infant, Newborn , Tissue and Organ Harvesting/ethics
4.
Cytotherapy ; 8(1): 57-61, 2006.
Article in English | MEDLINE | ID: mdl-16627345

ABSTRACT

BACKGROUND: Hematopoietic stem cells (HSC) have traditionally been frozen using the cryoprotectant DMSO in dextran-40, saline or albumin. However, the process of freezing and thawing results in loss of HSC numbers and/or function. METHODS: This study investigated the use of CryoStor for the freezing of HSC from cord blood (CB). CB donations (n = 30) were collected under an Institutional Ethics Committee-approved protocol, volume reduced and frozen using three different methods of cryoprotection. Aliquots were frozen with either 10% DMSO in dextran-40, 10% DMSO in CryoStor or 5% DMSO in CryoStor. Prior to freezing samples were separated for nucleated cell (NC) and CD34+ counts and assessment of CD34+ viability. Aliquots were frozen and kept in vapor phase nitrogen for a minimum of 72 h. Vials were rapidly thawed at 37 degrees C and tested for NC and CD34+ counts and CD34+ viability and colony-forming unit (CFU) assay. RESULTS: Cells frozen with CryoStor in 10% DMSO had significantly improved NC (P < 0.001), CD34+ recovery, viable CD34+ (P < 0.001) and CFU numbers (P < 0.001) compared with dextran in 10% DMSO. CryoStor in 5% DMSO resulted in significantly improved NC (P < 0.001) and CFU (P < 0.001). DISCUSSION: These results suggest that improved HSC recovery, viability and functionality can be obtained using CryoStor with 10% DMSO and that similar if not better numbers can be obtained with 5% DMSO compared with dextran-40 with 10% DMSO.


Subject(s)
Cryopreservation/methods , Cryoprotective Agents/pharmacology , Fetal Blood/cytology , Hematopoietic Stem Cells/cytology , Hematopoietic Stem Cells/drug effects , Antigens, CD34/metabolism , Cell Nucleus/metabolism , Cell Survival/drug effects , Colony-Forming Units Assay , Freezing , Humans
5.
J Paediatr Child Health ; 38(2): 166-9, 2002 Apr.
Article in English | MEDLINE | ID: mdl-12030999

ABSTRACT

OBJECTIVE: To correlate clinical presentation and therapeutic outcomes in children with a diagnosis of juvenile myelomonocytic leukaemia. METHODS: The medical records of 14 children who fulfilled the International Juvenile Myelomonocytic Leukaemia Working Group Criteria for a diagnosis of juvenile myelomonocytic leukaemia (JMML) presenting to a single institution were reviewed, and their clinical status at September 2000 was documented. RESULTS: The most common presenting features were hepatosplenomegaly and lymphadenopathy. Fifty per cent of cases presented in the first year of life. Nine of 14 patients initially received chemotherapy otherwise used in the treatment of acute myeloid or lymphoblastic leukaemia with no apparent benefit. All six patients who received conditioning therapy with chemotherapy alone, followed by allogeneic bone marrow transplant (BMT), are in complete remission at a median follow-up duration of 12 months (range 5-91 months). Five of six patients surviving post-allogeneic BMT received marrow from an unrelated donor. Only one of seven patients who did not receive BMT survived long-term. CONCLUSION: Children with a diagnosis of JMML should be treated with allogeneic BMT as soon as a suitable donor is found. The role of anti-leukaemic therapy in this disease, prior to BMT, requires further investigation in the context of a multicentre clinical trial.


Subject(s)
Bone Marrow Transplantation , Leukemia, Myelomonocytic, Acute/therapy , Treatment Outcome , Antineoplastic Agents/administration & dosage , Female , Hospitals, Pediatric , Humans , Infant , Leukemia, Myelomonocytic, Acute/drug therapy , Male , New South Wales , Remission Induction , Transplantation Conditioning , Transplantation, Homologous
6.
Br J Haematol ; 114(2): 433-43, 2001 Aug.
Article in English | MEDLINE | ID: mdl-11529868

ABSTRACT

A clinical goal for ex vivo expansion of cord blood (CB) CD34(+) cells is to shorten the period of neutropenia and thrombocytopenia following myeloablative therapy and transplantation. Prolongation of cytokine expansion leads to the production of greater numbers of cells, and should have an impact on neutrophil and platelet recovery. Furthermore, expansion of CD34(+) cells should support the continued production of neutrophils and platelets in the 6-week period following transplantation. We tested these hypotheses by characterization of the kinetics (human CD45(+) cells in the blood) and phenotype (CD45, CD34, CD61, CD33, CD19 and CD3) of human engraftment in the non-obese diabetic severe combined immunodeficient mouse (NOD-SCID) following 7 or 14 d of ex vivo expansion of CB CD34(+) cells. Mice transplanted with 14 d cells showed greater percentages of human CD45(+) cells in the blood, bone marrow and spleen than mice transplanted with unexpanded cells or 7 d cells. Prolonging cytokine exposure of CD34(+) cells and transplantation with increasing numbers of input cells facilitated the production of absolute numbers of CD34(+), CD33(+), CD61(+) and CD19(+) cells in vivo. Furthermore, analysis of SCID engrafting potential showed that prolongation of culture duration facilitates in vivo expansion of CD45(+), CD34(+) and CD19(+) cells after transplantation. It is anticipated that prolonged (2 weeks) ex vivo culture of CB will have a beneficial clinical effect.


Subject(s)
Antigens, CD34 , Cytokines/pharmacology , Fetal Blood/cytology , Hematopoietic Stem Cell Transplantation , Analysis of Variance , Animals , Cell Division/drug effects , Cells, Cultured , Female , Fetal Blood/immunology , Granulocyte Colony-Stimulating Factor/pharmacology , Humans , Lymphocyte Count , Mice , Mice, Inbred NOD , Mice, SCID , Spleen/immunology , Stem Cell Factor/pharmacology , Thrombopoietin/pharmacology , Time Factors
7.
Blood ; 97(10): 2962-71, 2001 May 15.
Article in English | MEDLINE | ID: mdl-11342418

ABSTRACT

In order to compare the outcomes of unrelated umbilical cord blood transplants (UCBTs) or bone marrow transplants, 541 children with acute leukemia (AL) transplanted with umbilical cord blood (n = 99), T-cell-depleted unrelated bone marrow transplants (T-UBMT) (n = 180), or nonmanipulated (UBMT) (n = 262), were analyzed in a retrospective multicenter study. Comparisons were performed after adjustment for patient, disease, and transplant variables. The major difference between the 3 groups was the higher number in the UCBT group of HLA mismatches (defined by serology for class I and molecular typing for DRB1). The donor was HLA mismatched in 92% of UCBTs, in 18% of UBMTs, and in 43% of T-UBMTs (P <.001). Other significant differences were observed in pretransplant disease characteristics, preparative regimens, graft-versus-host disease (GVHD) prophylaxis, and number of cells infused. Nonadjusted estimates of 2-year survival and event-free survival rates were 49% and 43%, respectively, in the UBMT group, 41% and 37% in the T-UBMT group, and 35% and 31% in the UCBT group. After adjustment, differences in outcomes appeared in the first 100 days after the transplantation. Compared with UBMT recipients, UCBT recipients had delayed hematopoietic recovery (Hazard ratio [HR] = 0.37; 95% confidence interval [95CI]: 0.27-0.52; P <.001), increased 100 day transplant-related mortality (HR = 2.13; 95CI: 1.20-3.76; P <.01) and decreased acute graft-versus-host disease (aGVHD) (HR = 0.50; 95CI: 0.34-0.73; P <.001). T-UBMT recipients had decreased aGVHD (HR = 0.25; 95CI: 0.17-0.36; P <.0001) and increased risk of relapse (HR = 1.96; 95CI: 1.11-3.45; P =.02). After day 100 posttransplant, the 3 groups achieved similar results in terms of relapse. Chronic GVHD was decreased after T-UBMT (HR = 0.21; 95CI: 0.11-0.37; P <.0001) and UCBT (HR = 0.24; 95CI: 0.01-0.66; P =.002), and overall mortality was higher in T-UBMT recipients (HR = 1.39; 95CI: 0.97-1.99; P <.07). In conclusion, the use of UCBT, as a source of hematopoietic stem cells, is a reasonable option for children with AL lacking an acceptably matched unrelated marrow donor.


Subject(s)
Bone Marrow Transplantation , Fetal Blood/cytology , Hematopoietic Stem Cell Transplantation , Leukemia/surgery , Treatment Outcome , Analysis of Variance , Child , Child, Preschool , Disease-Free Survival , Female , Graft vs Host Disease , Humans , Leukemia, Myeloid, Acute/mortality , Leukemia, Myeloid, Acute/surgery , Male , Precursor Cell Lymphoblastic Leukemia-Lymphoma/mortality , Precursor Cell Lymphoblastic Leukemia-Lymphoma/surgery , Recurrence , Registries , Retrospective Studies , Tissue Donors , Transplantation Conditioning
8.
Blood ; 97(6): 1598-603, 2001 Mar 15.
Article in English | MEDLINE | ID: mdl-11238097

ABSTRACT

Human leukocyte antigen (HLA)-identical sibling bone marrow transplantation is an effective treatment for Wiskott-Aldrich syndrome. However, most children with this disease lack such donors and many patients receive transplants from alternative donors. This study compared outcomes of HLA-identical sibling, other related donor, and unrelated donor transplantation for Wiskott-Aldrich syndrome. The outcome of 170 transplantations for Wiskott-Aldrich syndrome, from 1968 to 1996, reported to the International Bone Marrow Transplant Registry and/or National Marrow Donor Program were assessed. Fifty-five were from HLA-identical sibling donors, 48 from other relatives, and 67 from unrelated donors. Multivariate proportional hazards regression was used to compare outcome by donor type and identify other prognostic factors. Most transplant recipients were younger than 5 years (79%), had a pretransplantation performance score greater than or equal to 90% (63%), received pretransplantation preparative regimens without radiation (82%), and had non-T-cell-depleted grafts (77%). Eighty percent received their transplant after 1986. The 5-year probability of survival (95% confidence interval) for all subjects was 70% (63%-77%). Probabilities differed by donor type: 87% (74%-93%) with HLA-identical sibling donors, 52% (37%-65%) with other related donors, and 71% (58%-80%) with unrelated donors (P =.0006). Multivariate analysis indicated significantly lower survival using related donors other than HLA-identical siblings (P =.0004) or unrelated donors in boys older than 5 years (P =.0001), compared to HLA-identical sibling transplants. Boys receiving an unrelated donor transplant before age 5 had survivals similar to those receiving HLA-identical sibling transplants. The best transplantation outcomes in Wiskott-Aldrich syndrome are achieved with HLA-identical sibling donors. Equivalent survivals are possible with unrelated donors in young children.


Subject(s)
Bone Marrow Transplantation/immunology , Histocompatibility , Wiskott-Aldrich Syndrome/therapy , Actuarial Analysis , Bone Marrow Transplantation/adverse effects , Bone Marrow Transplantation/mortality , Child , Child, Preschool , Female , Follow-Up Studies , Humans , Infant , International Agencies , Karnofsky Performance Status , Male , Multivariate Analysis , Registries , Survival Rate , Tissue Donors , Transplantation, Homologous/adverse effects , Transplantation, Homologous/immunology , Transplantation, Homologous/mortality , Treatment Outcome , Wiskott-Aldrich Syndrome/complications , Wiskott-Aldrich Syndrome/mortality
9.
J Hematother Stem Cell Res ; 10(1): 157-65, 2001 Feb.
Article in English | MEDLINE | ID: mdl-11276369

ABSTRACT

Cytokine-mediated expansion has been proposed and successfully used to facilitate engraftment post transplantation. This study examined whether cryopreservation following expansion has a detrimental effect on the ability of cells to engraft, using the NOD-SCID mouse model. Cord blood (CB) CD34(+) cells were incubated for 7 days with stem cell factor (SCF), flt-3 ligand (FL), and megakaryocyte growth and development factor (MGDF). Expanded CD34(+) cells were transplanted into NOD-SCID mice either fresh or following cryopreservation and thawing. After thawing, recovery of nucleated cells was 94%, of CD34 cells was 63%, and of day-14 progenitors was 17%. The loss of day-14 progenitor cells among the thawed expanded cells did not influence the kinetics of human engraftment in the mouse. Bone marrow (BM) of mice transplanted with thawed expanded CD34(+) cells (14 +/- 3.9%) showed significantly higher levels of human engraftment than mice transplanted with fresh expanded CD34(+) cells (1.5 +/- 0.5%, p = 0.0064). Thawed expanded CD34(+) cells had significantly higher SCID Engrafting Potential (SEP) than freshly expanded CD34(+) cells (p < 0.001). Results suggest that prior cryopreservation does not prevent expanded cells engrafting in NOD-SCID mice.


Subject(s)
Blood Preservation/methods , Fetal Blood/cytology , Hematopoietic Stem Cell Transplantation/standards , Animals , Antigens, CD34/blood , Blood Preservation/standards , Cell Culture Techniques , Cell Division , Cryopreservation/standards , Female , Graft Survival , Humans , Leukocyte Common Antigens/blood , Mice , Mice, Inbred NOD , Mice, SCID , Transplantation, Heterologous
10.
Cytometry ; 43(1): 69-81, 2001 Jan 01.
Article in English | MEDLINE | ID: mdl-11122486

ABSTRACT

BACKGROUND: Multiple cytokines are required for the growth and development of hematopoietic cells. The effect of many cytokines depends on the activity of other signaling pathways. These interactions are quantified using factorial experimental design and analysis. METHODS: Human umbilical cord blood (HUCB) CD34+ cells were cultured in fully defined media containing various combinations of recombinant cytokines as defined by resolution IV factorial (2(7-3)(IV)) or full factorial (2(4)) design experiments. The cytokines studied were stem cell factor (SCF), interleukin (IL)-3, megakaryocyte growth and development factor (MGDF), granulocyte-colony stimulating factor (G-CSF), Flt-3 ligand, IL-6, IL-11, and erythropoietin (EPO). In vitro cell divisions were tracked by staining CD34+ cells with 5-(and-6)-carboxyfluorescein diacetate, succinimidyl ester, followed by flow cytometric analysis at 4 days of culture. In separate experiments, lineage commitment and differentiation were determined at 7 days by immunophenotype. RESULTS: In addition to the main effects of single cytokines, cytokine interactions were identified. There was a negative interaction between IL-3 and MGDF that resulted in a less than additive effect of these factors on erythroid and megakaryocytic development. The effect of Flt-3 ligand and SCF factor on CD34+ cell production was also less than additive, although the response to both cytokines was greater than single cytokines. The only positive interaction that was identified was between EPO and SCF, which resulted in the synergistic production of erythroid cells. CONCLUSIONS: Factorial analysis provides a powerful methodology to study the integration of multiple signals at the cellular and molecular level.


Subject(s)
Cytokines/pharmacology , Drug Interactions , Flow Cytometry/methods , Signal Transduction/drug effects , Analysis of Variance , Antigens, CD34/analysis , Cell Differentiation/drug effects , Cell Division/drug effects , Cell Lineage/drug effects , Cell Separation , Cell Survival/drug effects , Erythrocytes/cytology , Erythrocytes/drug effects , Erythrocytes/metabolism , Fetal Blood/cytology , Fetal Blood/drug effects , Fetal Blood/metabolism , Flow Cytometry/statistics & numerical data , Granulocytes/cytology , Granulocytes/drug effects , Granulocytes/metabolism , Hematopoiesis/drug effects , Hematopoietic Cell Growth Factors/metabolism , Hematopoietic Cell Growth Factors/pharmacology , Humans , Immunophenotyping , Megakaryocytes/cytology , Megakaryocytes/drug effects , Megakaryocytes/metabolism , Staining and Labeling
11.
Blood ; 96(4): 1254-8, 2000 Aug 15.
Article in English | MEDLINE | ID: mdl-10942365

ABSTRACT

Allogeneic bone marrow transplantation is an effective postremission strategy for patients with acute myelogenous leukemia (AML) in first complete remission (CR). The value of administering consolidation chemotherapy before human leukocyte antigen (HLA)-identical sibling transplantation is not established. Outcomes of patients with AML in first CR receiving no consolidation therapy, standard-dose cytarabine consolidation therapy, and high-dose cytarabine consolidation therapy before HLA-identical sibling transplantation were compared. Five-year treatment-related mortality rates were 30% (95% confidence interval [CI], 18% to 42%) in patients receiving no consolidation chemotherapy, 22% (95% CI, 17% to 28%) in those receiving standard-dose cytarabine consolidation, and 24% (95% CI, 17% to 31%) in those receiving high-dose cytarabine (P = NS). Five-year cumulative incidences of relapse were 19% (10% to 30%), 21% (16% to 27%), and 17% (11% to 24%), respectively (P = NS). Five-year probabilities of leukemia-free survival were 50% (36% to 63%), 56% (49% to 63%), and 59% (50% to 66%), respectively (P = NS). Five-year probabilities of overall survival were 60% (46% to 71%), 56% (49% to 63%), and 60% (51% to 67%), respectively (P = NS). The data indicate that postremission consolidation with cytarabine before allogeneic transplantation for AML in first CR is not associated with improved outcome compared to proceeding directly to transplantation after successful induction. (Blood. 2000;96:1254-1258)


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Bone Marrow Transplantation , Leukemia, Myeloid, Acute/therapy , Combined Modality Therapy , Disease-Free Survival , HLA Antigens , Histocompatibility Testing , Humans , Leukemia, Myeloid, Acute/pathology , Remission Induction , Transplantation, Homologous , Treatment Outcome
12.
J Clin Oncol ; 18(2): 340-7, 2000 Jan.
Article in English | MEDLINE | ID: mdl-10637248

ABSTRACT

PURPOSE: Preparative regimens involving total-body irradiation (TBI) produce significant late toxicities in some children who receive bone marrow transplants, including impaired growth and intellectual development. Busulfan is often used as an alternative to TBI, but there are few data regarding its relative efficacy. PATIENTS AND METHODS: We compared outcomes of HLA-identical sibling transplants for acute lymphoblastic leukemia (ALL) in children (< 20 years of age) who received cyclophosphamide plus TBI (CY/TBI) (n = 451) versus those who received busulfan plus cyclophosphamide (Bu/CY) (n = 176) for pretransplant conditioning. Patients received transplants between 1988 and 1995 and their results were reported to the International Bone Marrow Transplant Registry by 144 participating institutions. The CY/TBI and Bu/CY groups did not differ in gender, immune phenotype, leukocyte count at the time of diagnosis, chromosome abnormalities, remission status, or length of initial remission. T-cell depletion was used more frequently in the CY/TBI group; the Bu/CY group included a higher proportion of children who were less than 5 years of age. The median follow-up period was 37 months. RESULTS: The 3-year probabilities of survival were 55% (95% confidence interval [CI], 50% to 60%) with TBI/CY and 40% (95% CI, 32% to 48%) with Bu/CY (univariate P =.003). The 3-year probabilities of leukemia-free survival were 50% (95% CI, 45% to 55%) and 35% (95% CI, 28% to 43%), respectively (univariate P =.005). In a multivariate analysis, the risks of relapse were similar in the two groups (relative risk [RR], 1.30 for Bu/CY v CY/TBI; P =.1). Treatment-related mortality was higher in the Bu/CY group (RR, 1.68; P =.012). Death and treatment failure (relapse or death, inverse of leukemia-free survival) were more frequent in the Bu/CY group (RR, 1. 39; P =.017 for death; RR, 1.42; P =.006 for treatment failure). CONCLUSION: These data indicate superior survival with CY/TBI conditioning, compared with Bu/CY conditioning, for HLA-identical sibling bone marrow transplants in children with ALL.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Bone Marrow Transplantation , Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy , Whole-Body Irradiation , Adolescent , Adult , Busulfan/administration & dosage , Child , Child, Preschool , Combined Modality Therapy , Cyclophosphamide/administration & dosage , Female , Humans , Infant , Male , Recurrence , Retrospective Studies , Risk Assessment , Survival Analysis
13.
Transplantation ; 69(5): 927-35, 2000 Mar 15.
Article in English | MEDLINE | ID: mdl-10755552

ABSTRACT

BACKGROUND: Transplantation of human hematopoietic stem cells is the only true test of their long-term repopulation potential. Models are readily available to evaluate murine hematopoietic stem cells, but few exist that allow reliable quantification of human stem cells. The non-obese diabetic-severe combined immunodeficient (NOD-SCID) mouse model enables quantification of human hematopoietic stem cells, but the conditions that permit human engraftment in all animals have yet to be defined. The aims of the project were, therefore, to describe the variables that allow human engraftment in the NOD-SCID mouse model and the techniques that accurately quantify this engraftment. METHODS: NOD-SCID mice that had or had not received 250, 325, or 400 cGy irradiation received cord blood (CB) mononuclear or CD34+ cells i.v. or i.p. Mice were killed 6 weeks after transplantation, and the bone marrow, spleen, and thymus were harvested. Four-color flow cytometric analysis, semi-quantitative PCR, myeloid and erythroid progenitor, and stem cell assays were used to monitor human engraftment. RESULTS: A 250 or 325 cGy and i.v. injection of CB mononuclear or CD34+ cells is required to detect multilineage human engraftment in the bone marrow, spleen, or thymus of NOD-SCID mice. Four-color flow cytometric analysis and semi-quantitative PCR enable accurate detection of 0.1% human cells. Progenitor and stem cell assays provide functional information about the engrafted cells. CONCLUSIONS: Successful development of the NOD-SCID mouse model and techniques to assess human engraftment now allow it to be used reliably to analyze the effects of short-term cytokine exposure on the long-term repopulating capacity of CB stem cells.


Subject(s)
Hematopoietic Stem Cell Transplantation , Hybridization, Genetic , Mice, Inbred NOD , Mice, SCID , Transplantation, Heterologous , Animals , Antigens, CD34/analysis , Dose-Response Relationship, Radiation , Female , Flow Cytometry/methods , Hematopoietic Stem Cell Transplantation/methods , Hematopoietic Stem Cells/immunology , Humans , Injections , Mice , Radiation , Time Factors
14.
J Paediatr Child Health ; 35(1): 55-9, 1999 Feb.
Article in English | MEDLINE | ID: mdl-10234636

ABSTRACT

OBJECTIVE: To evaluate the clinical and diagnostic features of children presenting with haemophagocytic lymphohistiocytosis (HLH), evolution of the disease and outcomes in response to treatment. METHODOLOGY: The medical records of 12 children, aged 5 weeks to 13 years at diagnosis, with HLH managed at a single institution were reviewed. RESULTS: Presenting features were fever, hepatosplenomegaly, pancytopenia and hypertriglyceridemia or hypofibrinogenemia. Nine patients (75%) developed central nervous system (CNS) disease. Only one child with CNS disease survived. Five children had complete responses to therapy (42%), but all relapsed at a median of 1.5 months after starting treatment (range 2 weeks to 5 months). Two of the children treated are long-term survivors (17%), both after allogeneic bone marrow transplantation. All deaths occurred in the context of active disease. CONCLUSIONS: Haemophagocytic lymphohistiocytosis is a disease with a poor prognosis. Central nervous system complications are common and response to treatment usually is transient. This study provides support for the use of immunomodulatory therapy for remission introduction followed by consideration of allogeneic bone marrow transplantation.


Subject(s)
Histiocytosis, Non-Langerhans-Cell/diagnosis , Histiocytosis, Non-Langerhans-Cell/therapy , Adolescent , Antineoplastic Agents/therapeutic use , Bone Marrow Examination , Bone Marrow Transplantation , Child , Child, Preschool , Combined Modality Therapy , Diagnosis, Differential , Disease Progression , Female , Histiocytosis, Non-Langerhans-Cell/complications , Humans , Immunosuppressive Agents/therapeutic use , Infant , Male , Prognosis , Remission Induction/methods , Retrospective Studies , Survival Analysis , Treatment Outcome
15.
Bone Marrow Transplant ; 23(3): 211-20, 1999 Feb.
Article in English | MEDLINE | ID: mdl-10084251

ABSTRACT

We investigated the effect of short-term cytokine exposure on defined cord blood subpopulations. CD34+Thy1+, CD34+Thy1-, CD34+38-, CD34+38+, CD34+DR+, CD34+DR-, CD34+Rhodamine123 (Rh123)- and CD34+Rh123+ cells were incubated for 7 days in IMDM + 10% FCS + IL3 + IL6 + G-CSF + SCF (36GS) + flt3L. We evaluated LTHC-IC, immunophenotype and nucleated cell count for each cell population before and after cytokine exposure. Short-term exposure of CD34+38+, CD34+Thy1-, CD34+DR+, CD34+DR- and CD34+Rh123+ cells to 36GS causes a significant increase in cell number, whereas CD34+38-, CD34+Thy1+, and CD34+Rh123- cells show only a limited increase. CD34 status post cytokine incubation shows that CD34+38+, CD34+Thy1-, CD34+DR+, and CD34+Rh123+ fractions have a lower proportion of cells remaining CD34+ than CD34+38- CD34+Thy1+, CD34+DR- and CD34+Rh123- fractions. LTHC-IC analyses among input subpopulations show a higher frequency among CD34+38+, CD34+Thy1-, CD34+DR+, CD34+DR- and CD34+Rh123+ cells as compared with CD34+38-, CD34+Thy1+ and CD34+Rh123- cells. However, when LTHC-IC were evaluated after cytokine exposure, CD34+38-, CD34+Thy1+, and CD34+Rh123- cells showed a higher frequency of LTHC-IC as compared with other subpopulations. Addition of flt3L to 36GS doubled the numbers in all subpopulations without altering the proportion of CD34+ cells. Results suggest that CD34+38-, CD34+Thy1+ and CD34+Rh123- cells have a limited proliferative response to cytokines, the stem cell component of these populations is largely maintained and that expansion is derived from mature cell populations.


Subject(s)
Cytokines/pharmacology , Fetal Blood/cytology , Hematopoietic Stem Cells/drug effects , Cell Culture Techniques/methods , Cell Division/drug effects , Cells, Cultured , Flow Cytometry , Granulocyte Colony-Stimulating Factor/pharmacology , Hematopoietic Stem Cells/classification , Humans , Immunophenotyping , Interleukin-3/pharmacology , Interleukin-6/pharmacology , Membrane Proteins/pharmacology , Recombinant Fusion Proteins/pharmacology , Stem Cell Factor/pharmacology
16.
Bone Marrow Transplant ; 21(8): 841-3, 1998 Apr.
Article in English | MEDLINE | ID: mdl-9603413

ABSTRACT

Children with severe combined immunodeficiency (SCID) have profoundly diminished humoral and cellular immunity resulting in death during infancy unless immune reconstitution occurs by bone marrow transplantation (BMT). Thrombocytopenia post-bone marrow transplantation can be seen in relation to infection, graft-versus-host disease (GVHD) and rarely, as an autoimmune phenomenon due to immune dysregulation. We report two cases of severe AITP following BMT for SCID. Both cases developed large intracerebral hemorrhages from which one died. Autoimmune thrombocytopenia in this setting can be life-threatening and we recommend early and active intervention.


Subject(s)
Bone Marrow Transplantation/adverse effects , Purpura, Thrombocytopenic, Idiopathic/etiology , Severe Combined Immunodeficiency/therapy , Female , Humans , Infant
17.
Bone Marrow Transplant ; 21(2): 153-8, 1998 Jan.
Article in English | MEDLINE | ID: mdl-9489632

ABSTRACT

T and B lineage ALL cells express different levels of HLA-class II antigens, which may serve as targets for graft-versus-host disease (GVHD) and graft-versus-leukemia (GVL). The object of this study was to determine whether GVL effects after HLA-identical sibling bone marrow transplantation differed in T and B lineage ALL. We studied 1132 patients with ALL of T lineage (n = 416) or of B lineage (cALLa+) (n = 716) transplanted in first (n = 605) or second (n = 527) remission with bone marrow from an HLA-identical sibling donor, between 1982 and 1992, and reported to the IBMTR by 165 teams. Cox proportional hazards regression models were used to determine the relative risk (RR) of relapse in patients with acute (grades II-IV) or chronic GVHD vs patients without GVHD. Acute and chronic GVHD were considered as time-dependent covariates. Patients transplanted in first and second remission were analyzed separately. GVHD decreased relapse risks to a similar extent in T and B lineage ALL. For first remission transplants, relative risks of relapse for patients with vs those without GVHD was 0.34 for T lineage ALL and 0.44 for B lineage ALL. Corresponding relative risks in second remission transplants were 0.54 and 0.61. This study confirms earlier findings of an antileukemia effect of GVHD in ALL. This effect was similar in T lineage and B lineage ALL, despite probable differences in HLA-class II antigen expression.


Subject(s)
Bone Marrow Transplantation/immunology , Burkitt Lymphoma/therapy , Graft vs Host Reaction/immunology , Leukemia-Lymphoma, Adult T-Cell/therapy , Adolescent , Adult , Bone Marrow Transplantation/adverse effects , Burkitt Lymphoma/immunology , Child , Child, Preschool , Female , Graft vs Host Disease/etiology , Graft vs Host Disease/immunology , HLA Antigens , HLA-D Antigens , Humans , Infant , Leukemia-Lymphoma, Adult T-Cell/immunology , Male , Middle Aged , Recurrence , Registries , Risk Factors , Transplantation, Homologous
18.
Hematol Cell Ther ; 39(4): 193-7, 1997 Aug.
Article in English | MEDLINE | ID: mdl-9352327

ABSTRACT

To determine the optimal cell population for cytokine mediated expansion, we compared the use of Magnetic Cell Sorting (MACS) system enriched CD34+ human umbilical cord blood (HUCB) cells with that of MACS enriched, flow purified CD34+ HUCB cells. Both MACS enriched CD34+ cells and MACS enriched, flow purified CD34+ cells (mean starting purity of CD34+ SC 51.27 +/- 7.6% and 96.36 +/- 1.34% respectively n = 6) were incubated for seven days with Interleukin-1 (IL-1) + IL-3 + Stem Cell Factor (SCF) and showed a fold increase in the number of nucleated cells (10.02 +/- 2.6 and 18.23 +/- 4.73 respectively) and a reduction in the percentage of CD34+ cells (5.55 +/- 1.23% and 12.21 +/- 3.29% respectively). An increase in the absolute numbers of CD34+ cells (4.8 x 10(4) +/- 2.3 x 10(4)) was observed with MACS enriched CD34+ cells as compared to no change (1.3 x 10(5) +/- 8.8 x 10(4) with MACS enriched, flow purified CD34+ cells. An increase in IL-3 + GM-CSF + SCF responsive colony forming unit (CFU) (1.7 x 10(4) +/- 9.4 x 10(3) and 1.6 x 10(5) +/- 7.7 x 10(4) respectively) was also observed as compared with input values (1.5 x 10(4) +/- 1 x 10(4) and 2.3 x 10(4) +/- 8.9 x 10(3) respectively). We conclude that MACS enriched, flow sorted CD34+ HUCB cells have greater cytokine mediated expansion potential as measured by progenitor expansion, than MACS enriched CD34+ HUCB cells.


Subject(s)
Antigens, CD34/blood , Cytokines/physiology , Fetal Blood/immunology , Hematopoietic Stem Cells/immunology , Cell Count , Cell Nucleus , Cell Separation/methods , Fetal Blood/cytology , Humans , Magnetics
19.
20.
Hematol Cell Ther ; 39(3): 125-31, 1997 Jun.
Article in English | MEDLINE | ID: mdl-9262988

ABSTRACT

Cord blood (CB) has been successfully used to regenerate the hematopoietic system after myeloablative therapy. We investigated whether cytokine mediated expansion depletes CB of cells with stem cell characteristics. CB mononuclear cells (MNC) were enriched for quiescent (primitive) stem cells by incubation with 25 micrograms/ml 5-Fluorouracil (5-FU) and control CB MNC were incubated with media alone. Cells were then incubated for 7 days with Interleukin-1 (IL1)+IL3+Stem Cell Factor (SCF) and progenitor content, cell cycle status, nucleated cell count, immunophenotype and resistance to 25 micrograms/ml 5-FU (primitive stem cells) were evaluated before and after cytokine exposure. Incubation with IL1+IL3+SCF caused an increase (fold expansion) in committed (28.6 +/- 8.1), immature (5.8 +/- 1.8), and primitive progenitors (4.1 +/- 0.8) among control CB MNC compared to a decrease in committed progenitors (0 +/- 0) but an increase in both immature (8.4 +/- 4.8) and primitive progenitors (7 +/- 2.9) among 5-FU resistant CB MNC. An increase in the proportion of CD34+ cells occurred in both fractions. Expanded control CB MNC showed a significant increase in numbers of 5-FU resistant committed (p = 0.024), immature (p = 0.014) and primitive progenitors (p = 0.01) as compared with fresh CB MNC. Re-exposure of 5-FU resistant expanded CB MNC to 5-FU shows growth of some immature and primitive progenitors. Cytokine-mediated expansion of untreated and quiescent CB cells is possible and cytokine-mediated expansion does not deplete CB cells with stem cell characteristics.


Subject(s)
Cytokines/pharmacology , Fetal Blood/cytology , Fetal Blood/physiology , Hematopoietic Stem Cells/physiology , Antigens, CD34/biosynthesis , Cell Division/drug effects , Cell Division/physiology , Cell Nucleus/drug effects , Cell Nucleus/physiology , Drug Resistance , Drug Therapy, Combination , Female , Fluorouracil/pharmacology , Granulocyte-Macrophage Colony-Stimulating Factor/pharmacology , Hematopoietic Stem Cells/drug effects , Humans , Infant, Newborn , Interleukin-1/pharmacology , Interleukin-3/pharmacology , Leukocytes, Mononuclear/drug effects , Leukocytes, Mononuclear/physiology , Lymphocyte Activation/drug effects , Pregnancy , Recombinant Proteins/pharmacology , S Phase/drug effects , S Phase/physiology , Stem Cell Factor/pharmacology , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...